To better understand and treat HLHS, our team is taking a multifaceted approach that includes research into imaging and outcomes, human genetics, and regenerative strategies. The program's goal is to launch clinical trials that offer the latest advances in cell therapy to people with HLHS with the ultimate goal of delaying, or even preventing, the need for heart transplants in people with HLHS.
Recently, the Minneapolis Star Tribune visited Mayo Clinic to discuss the upcoming launch of the umbilical cord blood clinical trial. The resulting story highlights the necessity of integrating research and clinical practice, as well as patient participation and engagement, to accelerate new treatment options for those with HLHS.
Tags: cell therapy, clinical trials, Clinical Trials, Dr. Harold Burkhart, Dr. Patrick O'Leary, Dr. Tim Nelson, heart transplant, HLHS, HLHS research, Hypoplastic Left Heart Syndrome, Mayo Clinic, Minneapolis Star Tribune, regenerative medicine, stem cells, Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, umbilical cord blood